Emergent BioSolutions Inc.
EBS · NYSE · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Emergent BioSolutions Inc. at a glance
In FY2025, Emergent BioSolutions Inc. reported revenue of USD 743 mn, EBITDA of USD -435 mn, EBITDA margin of -58.5%.
| USD mn | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 1,044 | 743 | |||
| EBITDA | -1,125 | -435 | |||
| EBITDA margin | -107.8% | -58.5% | |||
| Free cash flow | 36 | 157 | |||
| ROIC | -257.8% | -39.2% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas